盐酸多奈哌齐(Donepezil Hydrochloride) - 药物靶点：AChE_在研适应症：痴呆，路易体病，阿尔茨海默症_专利_临床

概要

基本信息

简介多奈哌齐是一种小分子药物，作为乙酰胆碱酯酶抑制剂，有助于提高认知功能。该药物用于治疗轻度、中度和重度阿尔茨海默病患者，最初由日本的制药公司Eisai于1996年11月获得批准。尽管多奈哌齐盐酸盐不能治愈阿尔茨海默病，但它可以帮助控制与该病有关的某些症状，如记忆丧失、混乱和其他认知障碍。

药物类型

小分子化药

别名

ARIPEZIL、BNAG、Domepezil

+ [44]

靶点

AChE

作用机制

AChE抑制剂(乙酰胆碱酯酶抑制剂)

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症

痴呆路易体病阿尔茨海默症+ [1]

非在研适应症

晚期癌症注意缺陷障碍认知功能障碍+ [9]

原研机构

Eisai Co., Ltd.

在研机构

Aulbio Co., Ltd.初创企业重庆锐恩医药有限公司Sandoz Pty Ltd.

+ [12]

非在研机构

Pfizer Inc.

Teikoku Pharma USA, Inc.Teva Pharmaceuticals USA, Inc.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (1996-11-25),

阿尔茨海默症

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C24H30ClNO3

InChIKeyXWAIAVWHZJNZQQ-UHFFFAOYSA-N

CAS号120011-70-3

关联

359

项与盐酸多奈哌齐相关的临床试验

NL-OMON57117 / SuspendedN/AIIT

Randomized, double-blind, placebo-controlled, 2-way crossover study to characterize pharmacological reversal of biperiden-induced cognitive effects by donepezil in healthy elderly subjects - Biperiden challenge reversed by donepezil

开始日期2025-01-06

申办/合作机构

Centre for Human Drug Research

CTRI/2024/11/076541 / Not yet recruitingN/AIIT

Comparing the safety and efficacy of Donepezil,Memantine and fixed drug combination of Donepezil Memantine in dementia patients by using MoCA score - Prospective randomized open label study - nil

开始日期2024-11-22

申办/合作机构-

NCT06687993 / Not yet recruiting临床2期IIT

Acetylcholinesterase Inhibitor Treatment in Anorexia Nervosa: a Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

The goal of this clinical trial is to learn if the daily take of donepezil can treat adult patient suffering from anorexia nervosa. The main question it aims to answer is : do daily donepezil intake permit weight gain and reduction of food restriction rituals ? The treatment is a capsule comprising a drug limiting the degradation of a neurotransmitter called acetylcholine. This treatment has long been used to treat certain cognitive disorders. Researchers will compare two drug dosage and a look-alike capsule that contains no drug to see if the dose has an impact on the effect. Participants will take one capsule per day for three months will have regular hospital visits for cognitive and metabolic tests.

开始日期2024-11-01

申办/合作机构

Centre Hospitalier Saint-Anne

[+2]

100 项与盐酸多奈哌齐相关的临床结果

登录后查看更多信息

100 项与盐酸多奈哌齐相关的转化医学

登录后查看更多信息

100 项与盐酸多奈哌齐相关的专利（医药）

登录后查看更多信息

4,807

项与盐酸多奈哌齐相关的文献（医药）

2025-03-01·BEHAVIOURAL BRAIN RESEARCH

Donepezil treatment mitigates cholinergic system alterations, oxidative stress, neuroinflammation and memory impairment induced by branched-chain amino acid administration in rats

Article

作者: Alano, Carolina Giassi ; Streck, Emilio Luiz ; Canarim, Rafael Orestes ; Leipnitz, Guilhian ; Réus, Gislaine Zilli ; Effting, Pauline Souza ; De Pieri, Ellen ; Lemos, Isabela da Silva ; Machado-de-Ávila, Ricardo Andrez ; Botelho, Maria Eduarda Mendes ; Ribeiro, Catharina de Bem

Maple Syrup Urine Disease (MSUD) is an inherited metabolic disorder biochemically characterized by tissue accumulation of leucine, isoleucine, and valine and their derivatives. Patients present with neurological disabilities and treatment is limited. Donepezil, a drug used for neurodegenerative disorders, has been shown to improve memory and counteract oxidative stress and inflammation. In the present study, we investigated whether donepezil administration could improve alterations in the cholinergic system, oxidative stress, inflammation, and behavior changes in rats submitted to a chemical MSUD model based on the administration of branched-chain amino acids (BCAA) leucine, isoleucine, and valine. Our results showed a decrease in short- and long-term memory in the object recognition task in rats submitted to BCAA administration. We also verified an increase in acetylcholinesterase (AChE) activity and a decrease in choline acetyltransferase in the cerebral cortex of the BCAA control group. Increased reactive species production, alterations in the antioxidant defenses, and inflammation were further observed. Additionally, we found that donepezil treatment attenuated alterations in AChE activity, reactive species production, lipids oxidative damage, inflammation, and memory. Our findings contribute to the understanding of the pathophysiology of MSUD and suggest that donepezil is a potential pharmacological treatment for this disorder.

2025-02-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Streamlined turn-off fluorescence sensing of Donepezil: Enhancing evaluation in pharmaceutical formulations, quality control labs, and biological fluids at nano levels

Article

作者: Abu-hassan, Ahmed A. ; Abu-Hassan, Ahmed A ; Alshehri, Sultan ; Alsehli, Bandar R ; Mahdi, Wael A ; El Hamd, Mohamed A. ; El Hamd, Mohamed A ; Mahdi, Wael A. ; Abu-hassan, Ahmed A ; Alsehli, Bandar R.

Donepezil (DPZ) is used to treat Alzheimer's disease by increasing acetylcholine in the brain, necessitating precise analytical methods for its evaluation. This study aims to develop and validate a new turn-off fluorescence sensing method for quantifying DPZ, enhancing its evaluation in pharmaceutical formulations, quality control laboratories, and biological fluids. By leveraging the fluorescence-quenching interplay between DPZ and tetrabromofluorescein, the assay parameters were fine-tuned to enhance the development of an ion-associated complex. The developed method demonstrated a measurement range from 40.0 to 800.0 ng/mL, with detection and quantification limits of 12.6 ng/mL and 38.0 ng/mL, respectively. However, the successful application of the method to commercial DPZ tablets and plasma samples confirmed its effectiveness for both quality control labs and clinical research settings. It ensured accurate content uniformity and high precision, making it ideal for routine DPZ monitoring. In contrast to previous methods, this approach emphasizes environmental sustainability, evaluated using advanced tools like the Eco score scale, AGREE, RGB12, and BAGI. These tools facilitated a thorough assessment of the method's ecological impact and sustainability, underscoring its advantage over traditional methods in terms of environmental responsibility.

2025-02-01·BIOCHEMICAL PHARMACOLOGY

Implication of Let7b/AhR/ARNT/HMGB1/RAGE cascade in neuroplasticity disturbances induced by glucocorticoids and the promising reversible effect of 3,3 diindolymethane: Bidirectional crosstalk of Aryl hydrocarbon receptors

Article

作者: Azzam, May A ; Gad, Enas S ; Khidr, Haneen Y ; ElMonier, Asmaa A ; Abd-Elmawla, Mai A

Prolonged exposure to glucocorticoids (GC) disrupts neuronal architecture, hinders neuroplasticity, and triggers neuroinflammation. However, the precise underlying mechanisms have not been studied yet. The current study aimed to investigate the mechanisms of GC-induced neuroinflammatory effects by stimulating the miRNA let7b, aryl hydrocarbon receptor (AhR)/ARNT, HMGB1/RAGE, and other downstream targets. Rats were divided into 4 groups; control, GC (20 mg/kg, S.C.), 3,3'-diindolylmethane (DIM) 50 mg/kg/day, and donepezil (DNZ) 4 mg/kg/day for 21 days. Behavioral tests and histopathological investigations of cerebral cortex were done. Let7b, AhR, ARNT, and cytochrome A1A were estimated using qRT-PCR. HMGB1, RAGE, NQO1and NRF2 were estimated using ELISA, whereas GFAP and TNF-α by immunohistochemical analysis. Keap1 was estimated using Western technique. GSH and TBARS were assessed by colorimetric assay. In the current study, GC elevates the gene expressions of let7b, AhR, ARNT, and cytochrome A1A, along with the protein contents of HMGB1, RAGE, NQO1and NRF2. In addition, GC showed increased GFAP, TNF-α, and TBARS, together with decreased Keap1 and GSH. On the other side, DIM and DNZ reversed all the above-mentioned findings. Collectively, the study documents for the first time the effect of GC in upregulating let7b and activating the AhR/ARNT loop which subsequently stimulates RAGE/HMGB1 and NRF2/Keap1 cascade leading to stimulating further inflammatory and oxidative signaling pathways. Certainly, these effects are responsible for the behavioral fluctuations, the brain's histological disruption, altered neuroplasticity, and neuroinflammation induced by GC. Moreover, DIM conquers GC-induced neuroinflammation due to its characteristic role in modulating AhR and its downstream targets.

196

项与盐酸多奈哌齐相关的新闻（医药）

2024-12-16

·alphacognition.com

Alpha Cognition Announces Partial Exercise of Over-Allotment Option

VANCOUVER, British Columbia and Dallas, TX — December 16, 2024 (BUSINESS WIRE) — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of US$5.75 per share for an additional US$2.8 million in gross proceeds. After giving effect to the partial exercise of the over-allotment option, the Company sold an aggregate 9,184,159 common shares for gross proceeds of approximately US$52.8 million, before deducting underwriter discounts and other related expenses. The option closing date was December 16, 2024. The common shares began trading on The Nasdaq Capital Market on November 12, 2024, under the ticker symbol “ACOG”. The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYLTM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering. The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential use of proceeds of the Offering. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future. Contacts For further information: Michael McFadden, CEO Tel: 1-858-344-4375 info@alphacognition.com Titan Partners Contact: Tel: (929) 833-1246 info@titanpartnersgrp.com.

临床研究

2024-12-12

·Business Wire

Alpha Cognition Announces Voluntary Delisting from CSE

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17, 2024. The Company’s common shares will continue to trade on the Nasdaq under the symbol “ACOG”. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements: This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

上市批准

2024-12-11

·Business Wire

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Blast caused mTBI is considered to be the signature injury effecting soldiers where brain injury from explosive devices and artillery fire blast exposure is highly prevalent. ACI previously documented extensive functional and neuropathological protection, provided by ALPHA-1062 administration, following a single moderate traumatic brain injury. This second pre-clinical study in a rodent model, supported by the US Department of Defense (DOD), is a collaboration with investigators at the Seattle Institute of Biomedical and Clinical Research (affiliated with both the University of Washington and the Veterans Administration). The study is ongoing, with interim data demonstrating that ALPHA-1062 administration following 3 consecutive days of blast induced mTBI, results in a reduction of TBI associated neuropathology. Key findings demonstrated that, ALPHA-1062 administration reduced levels of neuroinflammation markers and neuropathology that occurs after blast trauma. High dose ALPHA-1062 reduced the levels of myeloid cell activation [CD 68] across multiple brain regions one month after blast. High dose ALPHA-1062 also demonstrated the ability to reduce midbrain astrogliosis [GFAP]. Astrogliosis is a process where brain cells called astrocytes become larger, multiply, and change in response to injury or disease in the brain. “These outcomes indicate a protective effect of ALPHA-1062, and demonstrated a reduction of neuropathology. The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury,” said Denis Kay, ACI’s Chief Scientific Officer. Further analysis of neuropathology and neurobehavioral [functional recovery] data is ongoing with the final study report due Q2/2025. About Alpha Cognition Inc. Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia. An intranasal formulation of ALPHA-1062 has demonstrated potent preservation brain structure and function in a preclinical model of moderate TBI, where enhanced recovery from the brain injury was also seen. The intranasal formulation is currently being evaluated for its ability to provide protection from a military relevant model of repeated mild TBI, in a program sponsored by the US Department of Defense. Neither Canadian Securities Exchange (the “CSE”) or the OTC Markets Group, accepts responsibility for the adequacy or accuracy of this release. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the TBI out-licensing plan and associated financing, the availability of funding pursuant to financings, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

100 项与盐酸多奈哌齐相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00670	盐酸多奈哌齐	N06DA02	DB00843

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
痴呆	美国	Corium International, Inc.	2022-03-11
路易体病	日本	Eisai Co., Ltd.	2014-09-19
阿尔茨海默症	美国	Eisai, Inc.	1996-11-25

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
认知功能障碍	临床3期	美国	Pfizer Inc.	2008-09-01
认知功能障碍	临床3期	美国	Eisai, Inc.	2008-09-01
唐氏综合征	临床3期	美国	Eisai, Inc.	2008-09-01
唐氏综合征	临床3期	美国	Pfizer Inc.	2008-09-01
注意缺陷障碍	临床3期	美国	Eisai Co., Ltd.	2008-07-02
注意缺陷障碍	临床3期	阿根廷	Eisai Co., Ltd.	2008-07-02
注意缺陷障碍	临床3期	澳大利亚	Eisai Co., Ltd.	2008-07-02
注意缺陷障碍	临床3期	加拿大	Eisai Co., Ltd.	2008-07-02
注意缺陷障碍	临床3期	智利	Eisai Co., Ltd.	2008-07-02
注意缺陷障碍	临床3期	法国	Eisai Co., Ltd.	2008-07-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04730635 (MK-0000-413, CTgov)	临床1期	阿尔茨海默症 \| 轻度认知障碍	44	Donepezil (Donepezil)	願壓壓壓顧製醖構醖廠(糧願遞製膚獵齋繭鹽網) = 選憲願夢繭窪顧艱鬱築襯顧網鹽鹹鏇齋醖製鑰 (遞夢鹽顧選鏇獵繭構築, 築網網襯衊衊餘鹹繭糧 ~ 築範願繭艱襯蓋構衊夢) 更多	-	2024-10-28
				Placebo (Placebo)	願壓壓壓顧製醖構醖廠(糧願遞製膚獵齋繭鹽網) = 齋憲製襯齋膚蓋鹽鬱憲襯顧網鹽鹹鏇齋醖製鑰 (遞夢鹽顧選鏇獵繭構築, 選衊鑰餘築夢襯範糧構 ~ 窪遞顧繭鹹膚壓廠膚獵) 更多
NCT04617782 (CTgov)	临床1期	-	60	Donepezil (Treatment A 5 mg TDS)	艱顧衊膚糧夢製選網鹽(遞繭願鹽淵壓範積網獵) = 壓顧齋淵構壓鑰網構遞壓鏇廠齋醖襯蓋顧窪鑰 (願糧選衊獵簾餘夢觸鏇, 製鬱襯鑰積網選繭窪壓 ~ 選鹽構鑰觸餘鹽衊鬱繭) 更多	-	2024-09-19
				Donepezil (Treatment B 10 mg TDS)	艱顧衊膚糧夢製選網鹽(遞繭願鹽淵壓範積網獵) = 繭簾構壓遞糧顧餘艱選壓鏇廠齋醖襯蓋顧窪鑰 (願糧選衊獵簾餘夢觸鏇, 衊襯鹽蓋遞壓鑰構網鹽 ~ 觸窪壓鏇憲窪夢構膚廠) 更多
NCT02822573 (Remember, CTgov)	临床3期	认知功能障碍 \| 乳腺癌	276	Donepezil 5 mg (Donepezil)	襯觸窪衊觸願糧餘鹹鹹(糧鬱齋願衊獵膚齋膚構) = 簾網齋網繭蓋簾艱選膚糧製鬱選淵衊簾構願衊 (淵餘獵壓鬱壓艱遞蓋觸, 顧構蓋製壓構積襯鏇鬱 ~ 鑰獵鹹窪鑰簾鏇夢築願) 更多	-	2023-09-13
				Placebo (Placebo)	襯觸窪衊觸願糧餘鹹鹹(糧鬱齋願衊獵膚齋膚構) = 選範遞窪蓋壓醖積選簾糧製鬱選淵衊簾構願衊 (淵餘獵壓鬱壓艱遞蓋觸, 鑰觸齋醖遞糧顧衊選蓋 ~ 顧膚夢構繭蓋範顧鬱簾) 更多
LIFE Study (AAIC2023)	N/A	阿尔茨海默症一线	-	Newly prescribed donepezil	觸齋簾餘蓋遞積鹹遞繭(鹹餘構餘廠窪廠築選鑰) = 簾選醖構顧範積繭鹽蓋觸觸齋觸鏇構鹹積製鹽 (齋醖鬱壓範夢憲襯膚夢 )	-	2023-06-16
AAIC2022	N/A	阿尔茨海默症	-	Donepezil hydrochloride loaded chitosan nanoparticles	鏇積齋網願襯製遞夢廠(齋選廠範憲製鏇觸鏇鏇) = 衊鏇餘衊選繭構窪構獵窪觸網餘齋遞鹽膚衊糧 (繭淵獵願糧憲餘膚選簾 ) 更多	-	2022-12-20
NCT04617782 (ANA2022)	临床1期	-	60	Donepezil TDS 10mg/d	蓋艱蓋網製繭窪網齋觸(網齋築遞衊鹽鑰淵鏇憲) = 淵繭願簾襯壓獵築廠鬱鏇鹹簾願範範憲繭壓積 (範範膚鑰製壓鏇蓋範襯, 100.5 ~ 117.4) 更多	积极	2022-09-14
				Donepezil TDS 5mg/d	蓋艱蓋網製繭窪網齋觸(網齋築遞衊鹽鑰淵鏇憲) = 簾範網獵鏇壓構網憲餘鏇鹹簾願範範憲繭壓積 (範範膚鑰製壓鏇蓋範襯, 97.6 ~ 113.6) 更多
NCT04617782 (ANA2022)	临床1期	-	-	Once-weekly 5-mg/d donepezil TDS	膚獵夢壓獵簾築廠廠顧(選壓鏇襯艱鹽齋鬱襯製) = combined skin irritation score of ≥ 3 reported in 51.7% and 54.5% of participants, 0.5 hours after 5- and 10-mg/d TDSs removal, respectively 鑰糧鏇獵襯構鑰醖鹹淵 (觸齋遞製網構鹽壓觸鹹 )	-	2022-09-14
				Once-weekly 10-mg/d donepezil TDS
NCT00477659 (CTgov)	临床4期	阿尔茨海默症	14	Donepezil hydrochloride	衊鏇築齋簾淵獵鹽獵壓(遞繭廠鏇簾觸築膚構獵) = 積鬱繭觸廠齋鹽壓醖淵醖淵繭築簾襯蓋齋廠糧 (蓋餘糧夢膚願製簾願築, 範範網膚鹹壓構鏇築觸 ~ 構餘選膚蓋簾襯網廠艱) 更多	-	2021-11-10
NCT00675025 (CTgov)	临床2期	认知功能障碍 \| 唐氏综合征	117	Donepezil hydrochloride (Aricept)	艱憲鏇艱廠構夢築鏇艱(廠鹽獵鑰鹽蓋壓選簾餘) = 餘壓夢繭鏇繭蓋齋夢構淵鹽艱鬱夢憲願憲顧繭 (蓋膚餘壓糧觸醖淵網壓, 選觸積積獵衊選鏇蓋顧 ~ 鬱簾艱艱糧膚膚選積獵) 更多	-	2021-03-29